Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
TRINALIN is an oral extended-release tablet combining azatadine maleate (a first-generation antihistamine) and pseudoephedrine sulfate (a nasal decongestant) approved in 1982. It is indicated for relief of symptoms associated with allergic rhinitis and other allergic conditions. The combination works by blocking histamine receptors to reduce itching and inflammation while stimulating alpha-adrenergic receptors to relieve nasal congestion.
With LOE approaching on a mature allergy product, commercial teams face contraction risk and should expect portfolio rationalization or transition to legacy-product management roles.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
TRINALIN linked jobs (604) span commercial leadership, manufacturing, and clinical operations, reflecting its mature status as a legacy brand requiring ongoing supply chain and compliance management. Career moves on this product typically lead to portfolio management, operational excellence, or transition roles rather than growth-stage advancement.
Worked on TRINALIN at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
604 open roles linked to this drug